Zum Hauptinhalt springen

Erythema chronicum migrans

Medizinische Fachkräfte

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our Gesundheitsartikel more useful.

Lesen Sie unten weiter

What is erythema chronicum migrans?

Erythema chronicum migrans is a characteristic clinical feature of Lyme disease (Lyme borreliosis). It is a distinctive rash, which occurs in the majority of people infected with Borrelia burgdorferi. This infection is transmitted to humans by the bite of a tick from the genus Ixodes.

  • Lyme disease is not common in the UK, with an estimated 2,000 to 3,000 new cases each year in England and Wales.

  • In the UK, areas where infection is acquired include Exmoor, the New Forest, the South Downs, parts of Wiltshire and Berkshire, Surrey, West Sussex, Thetford Forest, the Lake District, the North Yorkshire moors and the Scottish Highlands.

  • Infection may also be acquired abroad and mostly by holidaymakers. The majority are acquired in the USA, France, Germany, Scandinavia and other northern, eastern and central European countries. The infection can also be found in temperate forested areas of Asia, including Russia, China and Japan.

  • In Europe erythema chronicum migrans occurs as a presenting feature in up to 90% of those infected.2 Presentation does appear to depend upon the Borrelia species involved; therefore, in other parts of the world the rash may be a less common presenting sign.

Lesen Sie unten weiter

  • The characteristic manifestation of early Lyme disease (stage 1) is erythema chronicum migrans: a circular rash at the site of the infectious tick attachment, which radiates from the bite. It can appear within 3-36 days, but typically in 7-10.

  • It starts as a red macule or papule at the site of the tick bite after a (typically 7- to 10-day) delay.

  • The rash is round or oval, and pink, red or purple. There is often central sparing giving a target-like appearance, and the diameter is usually larger than 5 cm. The nature of the rash and the likelihood of its presence are partly dependent on the species involved and therefore differ between continents.

    Erythema migrans 'bullseye" rash of Lyme disease

    lyme disease erythema migrans

  • Untreated, this can last for some weeks, but eventually resolves.

  • Common areas include the popliteal fossa, groin, the axilla, the thorax and the trunk. The hairline and scalp are especially common in children.

  • It may be associated with other symptoms of infection, including fatigue, myalgia, arthralgia, headache, fever, stiff neck, and regional lymphadenopathy.

  • It may also be associated with later developments such as carditis, neurological disease, arthritis, and acrodermatitis chronica atrophicans (a swollen, bluish-red skin lesion on a distal extremity).

The National Institute for Health and Care Excellence (NICE) recommends diagnosing Lyme disease in people with erythema migrans that:4

  • Increases in size and may sometimes have a central clearing.

  • Is not usually itchy, hot or painful.

  • Usually becomes visible from 1 to 4 weeks (but can appear from 3 days to 3 months) after a tick bite and lasts for several weeks.

  • Is usually at the site of a tick bite.

In the absence of erythema migrans, the diagnosis of Lyme disease can be very difficult with non-specific clinical signs and symptoms that may or may not be supported by laboratory evidence.5

Lesen Sie unten weiter

For anyone with erythema migrans who have no evidence of focal symptoms of Lyme disease (eg neurological, cardiac, or joint involvement), investigations are not required and start treatment with oral antibiotics (see below).

Although the rash will resolve spontaneously over weeks or months, antibiotics help prevent progression to disseminated Lyme disease.

For the treatment of Lyme disease without focal symptoms (eg, neurological, carditis) but with erythema migrans and/or non-focal symptoms, NICE recommends:

  • First choice: oral doxycycline: 100 mg twice per day or 200 mg once per day for 21 days.

  • First alternative: oral amoxicillin: 1 g 3 times per day for 21 days.

  • Second alternative: oral azithromycin: 500 mg daily for 17 days (azithromycin should not be used to treat people with cardiac abnormalities associated with Lyme disease because of its effect on QT interval).

  • Avoid exposure to tick bites.

  • Remove ticks as soon as possible. Ticks take some time to transmit infection, so this may be prevented if removed quickly.

  • Antibiotic prophylaxis can be offered in endemic areas under certain circumstances if the tick bite can be positively identified.

Exclusive updates for healthcare professionals

Stay informed with the latest clinical updates, professional insights, and evidence-based guidance. The Patient Pro newsletter curates essential content for healthcare professionals—delivered straight to your inbox.

Bitte geben Sie eine gültige E-Mail-Adresse ein

By subscribing you accept our Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.

Weiterführende Literatur und Referenzen

  1. Lyme disease: guidance, data and analysis; Public Health England - now UK Health Security Agency (last updated 2022)
  2. The epidemiology, prevention, investigation and treatment of Lyme borreliosis in United Kingdom patients: a position statement by the British Infection Association; J Infect. 2011 May;62(5):329-38. doi: 10.1016/j.jinf.2011.03.006. Epub 2011 Mar 21.
  3. Lyme-Borreliose; NICE CKS, November 2022 (nur für UK-Zugang)
  4. Lyme-Borreliose; NICE Guidance (April 2018 - last updated October 2018)
  5. Bobe JR, Jutras BL, Horn EJ, et al; Recent Progress in Lyme Disease and Remaining Challenges. Front Med (Lausanne). 2021 Aug 18;8:666554. doi: 10.3389/fmed.2021.666554. eCollection 2021.
  6. Shapiro ED; Clinical practice. Lyme disease. N Engl J Med. 2014 May 1;370(18):1724-31. doi: 10.1056/NEJMcp1314325.
  7. Britisches Nationales Arzneimittelverzeichnis (BNF); NICE Evidenzdienste (nur in Großbritannien zugänglich)

Lesen Sie unten weiter

About the authorView full bio

Author image

Dr Colin Tidy, MRCGP

Allgemeinmediziner, Medizinischer Autor

MBBS, MRCGP, MRCP (Paediatrics), DCH

Dr. Colin Tidy ist ein NHS-Arzt mit Sitz in Oxfordshire.

About the reviewerView full bio

Author image

Dr Doug McKechnie, MRCGP

Medizinischer Autor

MA, MBBS, MSc, DRCOG, MRCP(UK), MRCGP(2021), FHEA

Dr. Doug McKechnie ist ein NHS-Hausarzt, der in London arbeitet. Er arbeitet klinisch in Vollzeit und ist außerdem stellvertretender Leiter des Moduls für klinische und berufliche Praxis an der University College London Medical School.

Artikelverlauf

Die Informationen auf dieser Seite wurden von qualifizierten Klinikern verfasst und begutachtet.

flu eligibility checker

Fragen, teilen, verbinden.

Durchsuchen Sie Diskussionen, stellen Sie Fragen und teilen Sie Erfahrungen zu Hunderten von Gesundheitsthemen.

Symptom-Checker für Patienten

Fühlen Sie sich unwohl?

Bewerten Sie Ihre Symptome online kostenlos